Clinical Trial Update: Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update examining the intraocular pressure effects and tolerability of bimatoprost 0.01% and preservative-free tafluprost unit-dose form…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• Bimatoprost 0.01% (bimatoprost)
• Tafluprost Unit Dose Preservative Free 15 Microgram/mL (tafluprost)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Ocular Hypertension, Glaucoma | Phase 4 | Status: UNKNOWN